KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables - Other (2016 - 2025)

Sarepta Therapeutics (SRPT) has 14 years of Receivables - Other data on record, last reported at $128.7 million in Q3 2025.

  • For Q3 2025, Receivables - Other rose 93.83% year-over-year to $128.7 million; the TTM value through Sep 2025 reached $128.7 million, up 93.83%, while the annual FY2024 figure was $34.6 million, 16.11% up from the prior year.
  • Receivables - Other reached $128.7 million in Q3 2025 per SRPT's latest filing, up from $73.3 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $128.7 million in Q3 2025 and bottomed at $8000.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $36.6 million, with a median of $29.1 million recorded in 2021.
  • Peak YoY movement for Receivables - Other: crashed 99.98% in 2021, then soared 41287.5% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $8000.0 in 2021, then skyrocketed by 41287.5% to $3.3 million in 2022, then surged by 800.03% to $29.8 million in 2023, then grew by 16.11% to $34.6 million in 2024, then skyrocketed by 271.97% to $128.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $128.7 million in Q3 2025, $73.3 million in Q2 2025, and $55.2 million in Q1 2025.